Abstract: The disclosure provides diagnostic and therapeutic agents for chronic lymphocytic leukemia (CLL). Further provided are biomarkers and a biomarker panel comprising G-protein coupled receptors (GPCRs) specifically expressed by CLL cells. Methods for diagnosing a disease stage of a CLL patient, progression, or prediction of clinical course and drug selection for the CLL patient, as well as methods for treating CLL, by targeting these GPCR biomarkers are also provided.

Abstract: The disclosure provides diagnostic and therapeutic agents for chronic lymphocytic leukemia (CLL). Further provided are biomarkers and a biomarker panel comprising G-protein coupled receptors (GPCRs) specifically expressed by CLL cells. Methods for diagnosing a disease stage of a CLL patient, progression, or prediction of clinical course and drug selection for the CLL patient, as well as methods for treating CLL, by targeting these GPCR biomarkers are also provided.

Abstract: Diagnostic and therapeutic agents for pulmonary arterial hypertension (PAH) are provided. Circulating microparticles (MPs) and/or the expression level of GPR75 are significantly increased in PAH-PASMC, but not normal PASMC, thus, providing a non-invasive diagnostic method for PAH. Furthermore targeting MPs and/or GPR75 with specific antibodies, inverse agonists or antagonists is a strategy to treat PAH.

Abstract: Provided herein, inter alia, are methods drawn to treatment of Th2-mediated and Th17-mediated diseases. Also provided herein is a mouse model that develops Th2 responses to environmental stimuli in a similar manner as human subjects.

Abstract: The present disclosure relates to compositions and methods for the diagnosis of schizophrenia. In particular, the instant disclosure is directed to identification of novel copy number variants of sequences associated with the VIPR2 gene, including certain micro-duplications and triplications, and correlation of these copy number variants with schizophrenia.

Abstract: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.

Abstract: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.